Current lentiviral vector systems (the third generation) generate virus particles using four plasmids and a producer cell line. The rationale behind four plasmids is to enhance safety, as ...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...

Researchers from Children's Hospital of Philadelphia (CHOP) have tested a preclinical model for an experimental gene therapy designed to treat multiple sulfatase deficiency (MSD), a disorder that ...

A new bioprocessing technique developed by a team of researchers could improve a range of therapies based on CAR-T cells.

1996b) , the vector pCMVΔR8.2 supplies all but the HIV envelope in trans, the vector pMD.G is used to produce the VSV-G pseudotype, while the transgene (lac Z) is inserted into the plasmid pHR’, which ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Tectonic Therapeutic (TECX – Research Report) today. The company’s ...

Inc. (Nasdaq: BLUE) today announced that it has completed the restatement of its consolidated financial statements for the ...

Researchers tested a preclinical model for an experimental gene therapy designed to treat multiple sulfatase deficiency (MSD), a disorder that affects the brain, lungs, skin, and skeleton with no ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Tectonic Therapeutic (TECX – Research Report), ...

Co-expressing NPY and its inhibitory receptor Y2 in excitatory hippocampal cells allows inhibitory autoregulation of ...

Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector ...